DUBLIN--(BUSINESS WIRE)--The "Impact of India on the Pharmaceutical Industry - Thematic Research" report has been added to ResearchAndMarkets.com's offering.

India has the third largest pharma market in the world by volume, after the US and China, driven by its strong manufacturing capabilities. It is the world's top vaccine manufacturer and among the largest producers and exporters of active pharmaceutical ingredient (API) and generics globally.

The country supplies over 60% of global vaccine demand, 40% of US generic demand, and 25% of all drugs in the UK. India has the third largest API industry globally, supplying 57% of APIs used by the World Health Organization (WHO) and its low-cost manufacturing of pharmaceuticals (about 33% lower than in western countries) continues to draw increasing foreign investment.

Approximately 97% of marketed products in India are generic and exports from India occupy 20% share by volume in the supply of generic medicines globally. Even though it is a leader in generics manufacturing, India lacks strong investment in the R&D of innovative drugs and needs to implement better-defined regulations to become more competitive in the biosimilars market.

The Indian biosimilars market is currently limited but will likely see moderate growth over the next few years, with 15 biosimilars currently in development. There is currently less focus on the domestic development of innovative drugs, as the industry is focused on manufacturing.

Key Questions Answered

• What industry, regulatory and technology trends define the Indian pharma market?
• Which deal types are the most prominent and shape India's pharma industry?
• What is the outlook of clinical trials and pipeline products in India?
• Why is manufacturing the main focus of the pharma industry in India?

Key Highlights

• India has the third largest pharma market in the world by volume, after the US and China, driven by its strong manufacturing capabilities.
• India is a leader in generics manufacturing. Better-defined regulations are needed for India to become more competitive in the biosimilars market and more investment is needed in the R&D of innovative drugs.
• The top therapy areas among marketed and pipeline products in India are central nervous system (CNS) and infectious disease, respectively.

Scope

• Overview of marketed products including top therapy areas and indications, regulatory and market access details as well as company profiles.
• Key topics covered for India's pharma market include trends, value chain, market analysis, opportunities, challenges and unmet needs and example deals.
• Pipeline and Clinical Trials analysis: Comprehensive data on emerging therapies under development by therapy areas, indications and companies as well as segmented by molecule type.
• Contract Manufacturing providing insightful review of the key manufacturing hubs in the country as well as of different types of services offered by contract development and manufacturing organizations (CDMO) in India.

Key Topics Covered:

• Executive Summary
• Introduction
• Trends
• Value Chain
• Market Analysis
• Clinical Trials
• Marketed Products
• Pipeline Products
• Contract Manufacturing in India
• Regulatory and Market Access
• Market Drivers and Barriers
• Companies
• Appendix

Companies Mentioned

• Sun Pharma
• Aurobindo
• Dr. Reddy's Laboratories
• GlaxoSmithKline
• Novartis
• Lupin
• Cipla
• Cadila Healthcare
• Micro Labs
• IntraLabs India Pvt

For more information about this report visit https://www.researchandmarkets.com/r/t4et2a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900